title: New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
abstract: BACKGROUND
  With the limited role of current treatment regimens and potential associated side effects of radiation in young children with ependymoma, considerable effort is being focused on new chemotherapeutic strategies and biologic agents.
  
  
  CONCLUSIONS
  Identification of those molecular changes underlying the development of ependymoma may, in time, lead to the development of not only novel therapeutic agents, but also specific patient-tailored therapies directed against known cell-signaling pathways.
authors.affiliation: Division of Neuro Oncology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Mailstop 260, Memphis, TN 38105, USA. karen.wright@stjude.org
authors.forename: Karen D
authors.initials: KD
authors.lastname: Wright
authors.forename: Amar
authors.initials: A
authors.lastname: Gajjar
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D004806:Ependymoma / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D007223:Infant; D011799:Quinazolines / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib